IP Library Patent Application 10517137
Patent Application
App. No. 10/517,137

Overactive bladder treating drug

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/517,137
Abstract

A therapeutic agent for overactive bladder containing tamsulosin or a pharmaceutically acceptable salt thereof as an effective ingredient.

Claims (8)

1 . A pharmaceutical composition for the therapy of overactive bladder where said composition contains tamsulosin or a pharmaceutically acceptable salt thereof as an effective ingredient.

2 . A pharmaceutical composition for the therapy of overactive bladder according to claim 1 in which said composition contains tamsulosin hydrochloride.

3 . A pharmaceutical composition for the therapy of overactive bladder according to claim 1 or claim 2 in which said composition contains muscarinic receptor antagonist.

4 . A pharmaceutical composition for the therapy of overactive bladder according to claim 3 in which said composition contains qunuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or its salt as an effective ingredient.

5 . The use of tamsulosin or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for overactive bladder.

6 . The use of tamsulosin or a pharmaceutically acceptable salt thereof for the manufacture of a medicament to be used in combination with muscarinic receptor antagonist in the treatment of overactive bladder.

7 . A method for the therapy of overactive bladder where said method includes administration of therapeutically effective amount of tamsulosin or a pharmaceutically acceptable salt thereof to a patient.

8 . A method for the therapy of overactive bladder where said method includes administration of therapeutically effective amount of tasulosin or a pharmaceutically acceptable salt thereof to a patient in combination with therapeutically effective amount of muscarinic receptor antagonist.

Assignments (2)
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2005
From: VAN MEETEREN, RIAN; VISSER, NICO J.; KAJII, HIROSHI; TAKIGUCHI, NOBUYUKI
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 017173/0138 →